HomeAbout UsPipelineBlogCareersContact Us

Pipeline

We are in the advanced stages of developing two fermentation-based Active Pharmaceutical Ingredients, namely, Tacrolimus and Sirolimus, that have clinical application within the field of immunology, oncology, and rare diseases. Our expected timeline for commercialization is the second quarter of 2024.

Tacrolimus

Tacrolimus is a biosynthetic macrolide with immunosuppressive properties. It is a calcineurin inhibitor that inhibits the Nuclear factor NFAT, thereby decreasing the synthesis of inflammatory cytokines.

Tacrolimus is used as primary therapy for renal and hepatic transplantation with 10-100 times higher efficacy than Cyclosprine.

Therapeutic Relevance

  • Organ Transplantation
  • Atopic dermatitis
  • Psoriasis
  • Ulcerative colitis

Rapamycin/Sirolimus

Sirolimus, also known as Rapamycin, is a biosynthetic small molecule with immunosuppressive, anti-fungal, and anti-proliferative properties. It is an mTOR inhibitor that blocks a protein complex called mTOR (mammalian target of Rapamycin), resulting in the prevention of cell-cycle progression from G1 to S phase downstream.

Therapeutic Relevance

  • Organ Transplantation
  • Lymphangioleiomyomatosis
  • Coronary Stent Coating
  • Venous malformations

Raspa Pharma

Sustainably Innovative

Navigation

HomeAboutpipelineblogCareersContact Us

Contact

Headquarters

204, Second Floor,
Shri Hari Tower,
Mira Bai Marg,
Lucknow – 226001,
Uttar Pradesh, India.

Subscribe to our newsletter

Be the first to learn the news about new features and product updates.


© 2023 • Raspa Pharma Pvt. Ltd. • All rights reserved.

Developed by PICKURPAGE